Theriva Biologics Inc

0.00 (0.00%)
Products, Regulatory

Synthetic Biologics Announces Positive Outcome Of DSMC Review In Clinical Trial Of Syn-004 In Allogeneic Hematopoietic Cell Transplant Recipients

Published: 09/27/2022 13:43 GMT
(SYN) - Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (dsmc) Review in Phase 1b/2a Clinical Trial of Syn-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients.
Synthetic Biologics Inc - Dsmc Reviewed Safety & Pharmacokinetic Data From Cohort 1 & Recommended Study May Proceed to Enroll Patients Into Cohort 2.
Synthetic Biologics Inc - No Aes Or Saes Were Determined to Be Related to Study Drug Treatment by Investigators.
Synthetic Biologics Inc - Syn-004 Was Not Observed in Blood Samples From Majority of Evaluable Patients.
Synthetic Biologics Inc - Meropenem Pharmacokinetics Were As Expected for This Patient Population.
Synthetic Biologics Inc - on Track to Initiate Second Cohort in Q4 2022.